he lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.
The index, which slightly underperformed the Dow Jones, had a smaller loss in August than in the previous month.
Spurred to develop new microfluidic chip technology, 10x told customers not to worry about the transition but told a court there would be "guaranteed hitches."
In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.
The life science segment saw strong sales in Droplet Digital PCR offset by sales the firm's process media product line.
The exact restrictions the injunction will place on 10x are not yet determined. 10x will also have to pay Bio-Rad additional damages, plus interest.
A federal judge upheld a $24 million jury award to Bio-Rad, while a trade court judge said Bio-Rad imported microfluidics that infringed 10x patents.
Invitae said this week that it completed its acquisition of Singular Bio on June 19.
A collaboration with ATAC-seq experts at the Broad Institute suggests the Bio-Rad assay can analyze tens of thousands of cells per experiment.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.